A New Era in Therapeutic Target Identification
Gain Insights Into:
- The evolution and future prospects of immuno-peptidomics in precision medicine.
- The impact of AI algorithms and advanced computational techniques on immuno-peptidomics.
Guest Speaker Insights:
- Get introduced to the field of immuno-peptidomics, led by our special guest, Martin Klatt, MD.
- Understand the practical application of ARDisplay in immuno-peptidomics through the lens of Dr. Klatt's research data.
Join the discussion on:
- Ways to streamline drug discovery processes through technological advancements in immuno-peptidomics.
- The potential implications of these developments for industry professionals and academics alike.
Access the webinar:
Meet our speakers:
Dr. Martin Klatt is a clinician, a scientist and a junior group leader at the Medical Department, Division of Hematology, Oncology and Tumor Immunology at Charité Universitätsmedizin in Berlin.
He received his Doctoral degree from the University of Tübingen (Germany) for his work in the Lab of Hans-Georg Rammensee. He held a postdoctoral position at the Memorial Sloan Kettering Cancer Center (New York City) after which he returned to Germany and joined Charité University. He is an author and co-author of over 30 publications in renowned peer-reviewed scientific journals and specializes in translational immuno-peptidomics with a focus on the major histocompatibility complexes (MHCs) and MHC-presented peptides. He is also interested in the interaction of T cells with pMHC complexes and how these interactions influence T cell activation.
Together with his research team, he utilizes tandem mass-spectrometry to define ideal targets for T cell-based therapies to design tumor-specific TCR T cells, as well as, TCRm CAR T cells. Recently, his research group was able to successfully design the NDC80-specific TCRm CAR T cells and together with Christopher Klebanoff’s group he defines and targets public neoepitopes derived from PIK3CA, KRAS, NRAS and more undisclosed targets.
With more than 20 years of research and diagnostic experience, he has gained extensive knowledge in tumor biology and MHC signaling. His areas of expertise include tumor-immune cell interactions, intracellular communication via extracellular vesicles and allogeneic transplantation. He has authored and co-authored over 40 scientific publications including book chapters and scripts covering his areas of specialization.
At Ardigen, he is a member of the Immuno-peptidomics group where he uses his scientific experience to support the creation of AI technologies to develop new approaches for cancer treatment.
Piotr Skoczylas has 5 years of experience in Life Science projects incorporating AI solutions into bioinformatic pipelines, incl. academic and commercial collaborations. He graduated with a Master of Science degree in Applied Mathematics from the Jagiellonian University. At Ardigen, he works as a Data Scientist specializing in Immuno-peptidomics, which includes being the Key Offering Manager of products such as ARDentify and ARDisplay - platforms for enhanced target identification and prediction of peptide presentation via HLA molecules.
Striving to have an actual impact on human health and quality of life, he represents a young generation of scientists who are aware of the insufficient progress that has been made toward effective cancer treatment. His multidisciplinary interests and strong theoretical foundations allowed him to become a core R&D team member and one of the main contributors to the development of a deep learning framework for modeling the antigen processing & presentation pathways. His expertise in applied mathematics enables him to extract valuable information from diverse biological data collections and apply this knowledge in machine learning techniques to seek new solutions within the immuno-oncology field.
